Watson Reports Positive Phase III Data for Prostate and Bladder Drugs

redorbit.com     May 22, 2008            

Watson Pharmaceuticals has announced positive data from clinical studies on two Phase III products - silodosin, an investigational treatment for benign prostatic hyperplasia and oxybutynin chloride topical gel, an investigational product for overactive bladder. [read full story]                

Full Coverage
                   

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic...

yahoo.com     May 21, 2008          

Wednesday May 21, 9:00 am ET - Innovative pipeline products highlight Watson's commitment to urology - The abstracts include a cardiac safety trial involving silodosin, an investigational treatment for benign prostatic hyperplasia (BPH, or prostate enlargement) and a pharmacokinetic study of...                

comments

                   

Watson Announces Positive Data For Its New Investigational Products For Benign Prostatic...

medicalnewstoday.com     May 22, 2008          

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that investigators presented clinical data on two Phase 3 products at the American Urological Association's annual meeting. The abstract (Steady-State Pharmacokinetics of an Investigational...                

comments

                   

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic...

drugs.com     May 22, 2008          

- Innovative pipeline products highlight Watson's commitment to urology - ORLANDO, Fla., May 21, 2008 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that investigators presented...                

comments